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Abstract
Background: Conjunctival amyloidosis is a very rare condition, generally unilateral, and presents mostly as an
isolated condition without systemic compromise. Our purpose is to present a new case of systemic amyloidosis
with a bilateral conjunctival involvement.
Case Presentation: A 66-years-old caucasian female complaining of conjunctival hemorrhage and chemosis in
both eyes for the last five years had been discontinuously treated with topical antibiotics and corticosteroids
without any evident improvement. She presented with a pink-yellow infiltration in the inferior conjunctiva of both
eyes. Conjunctival biopsy under optical microscopy revealed amyloid deposit, confirmed by Congo red staining.
Mucosal biopsy from esophagus and rectus confirmed amyloidosis by Congo red stain. Immunohistochemistry of
bone marrow biopsy showed an increased number of plasma cells and an over-expression of light chain kappa
subunit. She was treated with corticosteroids and lubrication with an improvement of symptoms. Ocular lesions
remained stable after a follow-up of 3 years.
Conclusions: Conjunctival amyloidosis is a rare entity that may be overlooked, and should be differentiated from
chronic conjunctivitis and conjunctival malignancies. Although it presents most frequently as a local process, a
systemic involvement should always be ruled out.
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Background
Amyloidosis is a rare group of disorders characterized
by the deposition of insoluble fibrillar proteins in a β-
pleated sheet configuration, known as amyloid, within
the extracellular and perivascular space, as the conse-
quence of a wrong folding process of normally soluble
proteins, and may affect virtually any organ or tissue of
the body [1–5].
Amyloidosis disorders are classified into three major
forms: local, systemic, and hereditary systemic amyloidosis
[2]. The acquired forms may be primary (immunologic)
and secondary (reactive) [2]. In primary amyloidosis (AL)
deposits contain immunoglobulin light chains, usually
lambda and kappa monoclonal types, resulting from the
abnormal production by plasmocytes in the bone marrow
[2, 6]. Secondary amyloidosis (AA) is formed from serum
protein A, an acute phase reactant protein that is synthe-
sized in response to longstanding inflammation [7]. In
hereditary amyloidosis protein deposits are constituted by
a mutant form of the transport protein transthyretin [8].
Ocular amyloidosis occurs most frequently as the local
deposition of amyloid in the same place where it origi-
nates or, rarely, may be part of a systemic disorder [3, 9].
Amyloid may accumulate in the eyelid, conjunctiva, cor-
nea, vitreous, or anterior orbit [3, 10].
Conjunctival amyloidosis is one of the most common
forms of ocular involvement, mostly occurring as a local
deposition of amyloid and rarely in association with sys-
temic involvement [3, 10–15]. Due to the rarity of con-
junctival amyloidosis, its diagnosis can often be
overlooked or confused with other conditions that may
affect the conjunctiva. It is more commonly observed in
middle-aged adult patients, presenting as an inflamma-
tory or malignant conjunctival entity [3, 11]. Besides,
conjunctival malignant lesions can lead to amyloidosis
and they should be ruled out [3, 12].
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The purpose of our study is to report a new case of sys-
temic amyloidosis with bilateral conjunctival involvement.
Case presentation
A 66-year-old Caucasian woman complaining of conjunc-
tival hemorrhage and chemosis in both eyes for the last
five years had been discontinuously treated with topical
antibiotics and corticosteroids without any evident
improvement.
At the time of her referral, best-corrected visual acuity
was 20/25 in both eyes. Biomicroscopy showed significant
bilateral and rather symmetric edema of the inferior bul-
bar and lower fornix conjunctiva with areas of pink-yellow
condensation and hemorrhages associated with follicular
reaction (Fig. 1a). A conjunctival swap was obtained to
rule out infection by common antibiotic resistant bacteria
or Chlamydia spp. As direct fluorescent antibodies for
Chlamydia spp were positive, she was put under treatment
with oral doxycycline 200 mg/day and topical azithromy-
cin 3 times/day for 20 days, without any improvement.
Conjunctival biopsy was undertaken and optical micros-
copy revealed amorphous eosinophilic material positive
for hematoxyline-eosin stain, with mild mono and poly-
morphonuclear inflammatory infiltrate and hemorrhagic
suffusion (Fig. 1b and 1c). After Congo red staining, the
samples showed a red-green birefringence and dichroism
under polarized light microscopy consistent with amyloid-
osis (Fig. 1d). No evidence of malignancy was observed.
Fig. 1 (a)Photograph of the patient showing in both eyes diffuse, yellow-pink diffuse mass extending from the inferior bulbar conjunctiva to the
lower fornix with areas of waxy-yellow condensations, prominent intrinsic vessels and subconjunctival hemorrhage. b Optical microscopy of
conjunctival biopsy shows an amorphous eosinophilic material with mild mono and polymorphonuclear inflammatory infiltrate and hemorrhagic
suffusion; (H&E; original magnification x100). c A higher magnification shows the amorphous material replacing the normal stroma of the
conjunctiva; (H&E; original magnification x400). d Polarization microscopy of conjunctival specimen stained with Congo red shows a characteristic
red-green birefringence and dichroism of amyloid
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A complete systemic evaluation was carried out. Liver
and heart function evaluation was normal. Immunofixa-
tion of blood samples revealed polyclonal hypergamma-
globulinemy, and no monoclonal bands were observed
by immunofixation of urine sample. Mucosal biopsy
from esophagus, and rectus confirmed amyloidosis by
the Congo red staining (not shown). In order to rule out
multiple myeloma or plasma cells dyscrasia, a bone mar-
row biopsy was obtained showing a positive expression
of CD 138+ (Fig. 2a), a well known marker for identifica-
tion and quantification of plasma cells in bone marrow
and other tissues, as well as an increased population of
plasma cells with over-expression of the light chain
kappa subunit (Fig. 2b).
The patient was treated with topical lubrication and
the ocular lesions of both eyes remained stable after a
follow-up of 3 years. She continues with periodical clin-
ical controls to assess the eventual manifestation and
progression of the systemic disease.
Discussion
Conjunctival amyloidosis, predominantly affecting
middle-aged adults, usually begins at the fornices,
spreading to the bulbar and palpebral conjunctiva [3].
This progression appears to affect more deeply the pal-
pebral than the bulbar conjunctiva [3, 16]. In our pa-
tient, a bilateral diffuse pink-yellow infiltration with
hemorrhagic areas was found throughout the lower bul-
bar conjunctiva without affecting the palpebral function
and position, in contrast with the findings of Demirci et
al [4] that observed a unilateral involvement in all of
their six cases.
Associated spontaneous conjunctival hemorrhages,
as observed in our patient, are a common finding
that may be explained by the fact that amyloid infil-
tration of vessel walls induces rigidity and disruption
of conjunctival vessels [3]. A complete systemic evalu-
ation to discard a primary systemic form of the dis-
ease is recommended [10] as conjunctival amyloidosis
might be an early manifestation of systemic amyloid-
osis [3]. In our case, the initial presentation of con-
juctival amyloidosis led to the systemic findings that
were asymptomatic. Only five cases have been re-
ported as systemic amyloidosis with conjunctival in-
volvement [3, 12–15].
Even though the condition may be clinically suspected,
a tissue biopsy of the involved organ should be taken to
confirm the diagnosis. In systemic disease the sampling
can be performed directly in the organ or tissue affected,
or in a clinically uninvolved site such as subcutaneous
fat, minor salivary glands or rectal mucosa [1, 3]. Fur-
thermore, testing for monoclonal protein population
should be determined by serum and urine protein elec-
trophoresis and immunofixation [1]. In our patient,
immunofixation of blood samples only revealed poly-
clonal hypergammaglobulinemy, and rectal and esopha-
geal mucosal biopsies confirmed the diagnosis of
systemic amyloidosis. In addition, immunohistochemical
studies of bone marrow biopsies showed an increased
population of plasma cells with the amyloidogenic over-
expression of the subunit kappa.
There is still no consensus on the management of con-
junctival amyloidosis and none of the available treatments
are radical. Some authors recommend conservative
Fig. 2 Immunohistochemistry of bone marrow biopsy. a Staining with specific antibodies for CD 138 show increased number of plasma cells (in
brown; x400). b Over-expression of immunoglobulin light chain kappa subunit (in orange-brown; x400)
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treatment using lubricants and topical anti-inflammatories
[3]. Others believe that a more aggressive treatment
should be done in order to prevent progression or recur-
rence [17]. Cryotherapy, [18] radiotherapy, [19] surgical
debulking, [20] and mucous membrane graft implantation,
[21] are among the techniques that could be used. A con-
servative topical treatment was offered to our patient, as
lesions remained stable over time and the patient referred
no major ocular complaints.
Conclusions
Conjunctival amyloidosis is a rare entity that may be
overlooked and should be differentiated from chronic
conjunctivitis and conjunctival malignancies. Although
commonly a local process, a systemic involvement
should always be ruled out.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any of the accom-
panying images. A copy of the written consent is avail-
able for review by the Editors of BMC Ophthalmology.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LJC participated in the conception and design of the work, drafted the
manuscript, participated in the follow-up of patient acquisition, performed in
the analysis and interpretation of data, participated in figures selection and
edition; manuscript revision and text editing; final manuscript critical revision
and correction. JPM performed clinical diagnosis, treatment and follow-up of
patient, participated in the conception and design of the work, carried out
the analysis and interpretation of data, participated in the final manuscript
critical revision, and provided the clinical picture. EE participated in the fol-
low-up of patient, acquisition, analysis and interpretation of data, in writ-
ing of the manuscript and text editing, and in the final manuscript
critical revision and correction. RM participated in the follow-up of
patient, acquisition, analysis and interpretation of data, and in the final
manuscript critical revision and correction. MEG-C participated in the
follow-up of patient, in the acquisition, analysis and interpretation of
data, and in the manuscript revision and correction. MP performed
hystopathologic studies, carried out the analysis and interpretation of
data and selection of hystopathologic images, and participated in
manuscript revision. HMS participated in the writing of the manuscript
and text editing, and in the final manuscript critical revision and
correction. JAU-Z participated in the conception and design of the
work; carried out the analysis and interpretation of data; participated
in the writing of the manuscript and text editing, and in the final
manuscript critical revision and correction. All authors read and
approved the final manuscript, and are accountable for all aspects of
the work in ensuring that questions related to the accuracy or
integrity of any part of the work were appropriately investigated and
resolved.
Acknowledgements
The authors are grateful to Dr. Ana V. Sanchez and Dr. Ana B. de Diller from
the Department of Pathology, Hospital Privado Centro Medico de Cordoba,
Argentina, for their invaluable assistance concerning bone marrow biopsy
analysis and imaging.
Author details
1Department of Ophthalmology, University Clinic Reina Fabiola, Universidad
Catolica de Cordoba, Oncativo 1248, Cordoba 5000, Argentina. 2Centro
Medico de Patologia y Citopatologia, Cordoba, Argentina. 3CIBICI-CONICET,
Faculty of Chemical Sciences, Universidad Nacional de Cordoba, Cordoba,
Argentina.
Received: 5 April 2015 Accepted: 14 July 2015
References
1. Goveric PD. An overview of amiloidosis. UpToDate® Wolters Kluwer Health.
2013; http://www.uptodate.com/contents/an-overview-of-amyloidosis
2. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et
al. Amyloid: Toward terminology clarification. Report from the
Nomenclature Committee of the International Society of Amyloidosis.
Amyloid. 2005;12:1–4.
3. Leibovitch I, Selva D, Goldberg RA, Sullivan TJ, Saeed P, Davis G, et al.
Periocular and orbital amyloidosis: clinical characteristics, management, and
outcome. Ophthalmology. 2006;113:1657–64.
4. Demirci H, Shields CL, Eagle Jr RC, Shields JA. Conjuctival amyloidosis: report
of six cases and review of the literature. Surv Ophthalmol. 2006;51:419–33.
5. Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis
and targeted therapy. Annu Rev Pathol. 2015;10:321–44.
6. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins:
proof of homology with immunoglobulin light chains by sequence
analyses. Science. 1971;172:1150–1.
7. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore
JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J
Med. 2007;356:2361–71.
8. Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et
al. Online registry for mutations in hereditary amyloidosis including
nomenclature recommendations. Hum Mutat. 2014;35:E2403–12.
9. Al-Nuaimi D, Bhatt PR, Steeples L, Irion L, Bonshek R, Leatherbarrow
B. Amyloidosis of the orbit and adnexae. Orbit. 2012;31:287–98.
10. Aryasit O, Preechawai P, Kayasut K. Clinical presentation, treatment, and
prognosis of periocular and orbital amyloidosis in a university-based referral
center. Clin Ophthalmol. 2013;7:801–5.
11. Ray M, Tan AW, Thamboo TP. Atypical presentation of primary conjuctival
amiloidosis. Can J Ophthalmol. 2012;47:e2–4.
12. Abdallah AO, Westfall C, Brown H, Muzaffar J, Atrash S, Nair B. Unilateral
conjunctival AL kappa amyloidosis with trace evidence of systemic
amyloidosis. Am J Case Rep. 2012;13:102–5.
13. Purcell Jr JJ, Birkenkamp R, Tsai CC, Riner RN. Conjunctival involvement in
primary systemic nonfamilial amyloidosis. Am J Ophthalmol. 1983;95:845–7.
14. Iijima S. Primary systemic amyloidosis: a unique case complaining of diffuse
eyelid swelling and conjunctival involvement. J Dermatol. 1992;19:113–8.
15. Shields JA, Eagle RC, Shields CL, Green M, Singh AD. Systemic amyloidosis
presenting as a mass of the conjunctival semilunar fold. Am J Ophthalmol.
2000;130:523–5.
16. Rodrigues G, Sanghvi V, Lala M. A rare cause of unilateral upper and lower
eyelid swelling: isolated conjuctival amyloidosis. Korean J Ophthalmol.
2001;15:38–40.
17. Patrinely JR, Koch DD. Surgical management of advanced ocular adnexal
amyloidosis. Arch Ophthalmol. 1992;110:882–5.
18. Fraunfelder FW. Liquid nitrogen cryotherapy for conjunctival amyloidosis.
Arch Ophthalmol. 2009;127:645–8.
19. Khaira M, Mutamba A, Meligonis G, Rose GE, Plowman PN, O´Donnell H. The
use of radiotherapy for the treatment of localized orbital amyloidosis. Orbit.
2008;27:432–7.
20. Murdoch IE, Sullivan TJ, Moseley I, Hawkins PN, Pepys MB, Tan SY, et al.
Primary localized amyloidosis of the orbit. Br J Ophthalmol. 1996;80:1083–6.
21. Seider N, Beiran I, Kaltreider SA. Advanced localized primary conjunctival
amyloidosis: surgical rehabilitation using mucous membrane graft
implantation. Isr Med Assoc J. 2006;8:439–40.
Correa et al. BMC Ophthalmology  (2015) 15:77 Page 4 of 4
